{
    "id": "4de67c3c-cad0-4da2-8eab-da7a184135bc",
    "indications": "linezolid oxazolidinone-class antibacterial indicated adults children treatment following infections caused susceptible gram-positive bacteria : nosocomial pneumonia ( 1.1 ) ; community-acquired pneumonia ( 1.2 ) ; complicated skin skin structure infections , including diabetic foot infections , without concomitant osteomyelitis ( 1.3 ) ; uncomplicated skin skin structure infections ( 1.4 ) ; vancomycin-resistant enterococcus faecium infections . ( 1.5 ) limitations ( 1.6 ) : • linezolid indicated treatment gram-negative infections . • safety efficacy linezolid formulations given longer 28 days evaluated controlled trials . reduce development drug-resistant bacteria maintain effectiveness linezolid formulations antibacterial drugs , linezolid used treat prevent infections proven strongly suspected caused bacteria . ( 1.7 )",
    "contraindications": ", route , frequency infection pediatric patients ( birth 11 years age ) adults adolescents ( 12 years older ) duration ( days ) nosocomial pneumonia 10 mg/kg intravenous oral every 8 hours 600 mg intravenous oral every 12 hours 10 14 community-acquired pneumonia , including concurrent bacteremia complicated skin skin structure infections vancomycin-resistant enterococcus faecium infections , including concurrent bacteremia 10 mg/kg intravenous oral every 8 hours 600 mg intravenous oral every 12 hours 14 28 uncomplicated skin skin structure infections less 5 yrs : 10 mg/kg oral every 8 hours 5–11 yrs : 10 mg/kg oral every 12 hours adults : 400 mg oral every 12 hours adolescents : 600 mg oral every 12 hours 10 14",
    "warningsAndPrecautions": "linezolid tablets available follows : 600 mg ( white , capsule-shaped , film-coated tablet debossed `` zyv `` one side `` 600 `` ) 20 tablets hdpe bottle ndc 59762-1307-1 unit dose packages 20 tablets ndc 59762-1307-2",
    "adverseReactions": "• known hypersensitivity linezolid product components . ( 4.1 ) • patients taking monoamine oxidase inhibitors ( maoi ) within two weeks taking maoi . ( 4.2 )",
    "ingredients": [
        {
            "name": "LINEZOLID",
            "code": "ISQ9I6J12J"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        }
    ],
    "organization": "Mylan Pharmaceuticals Inc.",
    "name": "Linezolid",
    "effectiveTime": "20250527",
    "indications_original": "Linezolid is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 ) Limitations of Use ( 1.6 ): • Linezolid is not indicated for the treatment of Gram-negative infections. • The safety and efficacy of linezolid formulations given for longer than 28 days have not been evaluated in controlled clinical trials. To reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid formulations and other antibacterial drugs, linezolid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.7 )",
    "contraindications_original": "Dosage, Route, and Frequency of Administration Infection Pediatric Patients (Birth through 11 years of Age) Adults and Adolescents (12 years and Older) Duration (days) Nosocomial pneumonia 10 mg/kg intravenous or oral every 8 hours 600 mg intravenous or oral every 12 hours 10 to 14 Community-acquired pneumonia, including concurrent bacteremia Complicated skin and skin structure infections Vancomycin-resistant Enterococcus faecium infections , including concurrent bacteremia 10 mg/kg intravenous or oral every 8 hours 600 mg intravenous or oral every 12 hours 14 to 28 Uncomplicated skin and skin structure infections less than 5 yrs: 10 mg/kg oral every 8 hours 5–11 yrs: 10 mg/kg oral every 12 hours Adults: 400 mg oral every 12 hours Adolescents: 600 mg oral every 12 hours 10 to 14",
    "warningsAndPrecautions_original": "Linezolid Tablets are available as follows:\n                  600 mg (white, capsule-shaped, film-coated tablet debossed with \"ZYV\" on one side and \"600\" on the other)\n                  \n                     \n                     \n                     \n                        \n                           \n                              20 tablets in HDPE bottle\n                           \n                           \n                              NDC 59762-1307-1\n                           \n                        \n                        \n                           \n                              Unit dose packages of 20 tablets\n                           \n                           \n                              NDC 59762-1307-2",
    "adverseReactions_original": "• Known hypersensitivity to linezolid or any of the other product components. ( 4.1 ) • Patients taking any monoamine oxidase inhibitors (MAOI) or within two weeks of taking an MAOI. ( 4.2 )"
}